STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
STAT News · LC · trust 48/100
The FDA has rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis.
Read the original at STAT News →
Open in TruthVane →